Audentes Therapeutics Obtains $30,000,000 Series A Funding Round

  • Feed Type
  • Date
    7/19/2013
  • Company Name
    Audentes Therapeutics
  • Mailing Address
    Undisclosed San Francisco, CA 94101
  • Company Description
    Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology.
  • Website
    http://www.audentestx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    This funding will allow the Company to further advance its two lead programs, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs.
  • M&A Terms
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    Versant Ventures
  • Venture Investor
    5AM Ventures

By posting a comment, you agree to our terms and conditions.